UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ______________________ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charte ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2021 Earnings Conference Call August 4, 2021 8:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - CEO Anthony Doyle - CFO Charlie Gayer - Chief Commercial Officer Bill Sheridan - Chief Medical Officer Helen Thackray - Chief R&D Officer Conference Call Participants Ken Cacciatore - Cowen & Company Brian Cheng - Cantor Fitizgerald Liisa Bayko - Evercore ISI Jessica Fye - JPMorgan Serge Belanger - Needham & Company Ta ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2021 Results Conference Call May 6, 2021 8:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - CEO Anthony Doyle - CFO Charlie Gayer - Chief Commercial Officer Dr. Bill Sheridan - Chief Medical Officer Megan Sniecinski - Chief Business Officer Dr. Helen Thackray - Chief R&D Officer Conference Call Participants Jessica Fye - JP Morgan Liisa Bayko - Evercore ISI Ken Cacciatore - Cowen & Co Serge Belanger - Needham & C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ______________________ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2020 Earnings Conference Call February 25, 2021 8:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - CEO Anthony Doyle - CFO Bill Sheridan - Chief Medical Officer Megan Sniecinski - Chief Business Officer Charlie Gayer - Chief Commercial Officer Conference Call Participants Jessica Fye - JPMorgan Brian Cheng - Bank of America David Dai - Barclays Maury Raycroft - Jefferies Operator Ladies and gentlemen, thank you f ...